PSA-responsive and PSMA-mediated multifunctional liposomes for targeted therapy of prostate cancer

Roles of ligand and TPGS of micelles in regulating internalization, penetration and accumulation against sensitive or resistant tumor and therapy for multidrug resistant tumors

“…The folate-modified DSPEePEG (DSPEePEG-folate) was synthetized and characterized as the previous paper [20,29]. Successful synthesis was evidenced by the molecular shifts in the MALDI-TOF MS analysis (Fig.…”

Dual-modified liposomes with a two-photon-sensitive cell penetrating peptide and NGR ligand for siRNA targeting delivery

“…For the qRT-PCR assessment, the method has been reported by Xiang et al [22], with minor modifications. Briefly, the analysis was performed on the IQ5 real-time PCR detection system (Bio-Rad), and the relative gene expression was quantified by the 2 ÀDDCt method using the IQ5 Optical System Software version 2.0 (Bio-Rad).…”

“…Tumor fragments were processed for total mRNA or protein extraction followed by qRT-PCR and Western blot assays, respectively. To analyze the c-myc mRNA, the extracted mRNA samples were individually normalized to the same 260 nm absorbance value and detected by qRT-PCR as described in a previous report [22]. To assess the c-myc protein expression, the selected tumor tissues were homogenized in 1 mL of NP-40 Lysis Buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1% NP-40, sodium pyrophosphate, b-glycerophosphate, sodium orthovanadate, sodium fluoride, EDTA and leupeptin) (Beyotime, China) with PMSF (1 mM).…”

Study on the prostate cancer-targeting mechanism of aptamer-modified nanoparticles and their potential anticancer effect in vivo

“…7 Importantly, PSMA is continually recycled from the plasma membrane and constitutively endocytosed in PSMA-positive LNCaP cells, making it an attractive portal to deliver molecules intracellularly. 8,9 The introduction of various biological ligands or antibodies into drug delivery systems has provided an opportunity for the targeted delivery of miRNA to PCa cells.…”

“…10 Such ligands are 5432 Wu et al recognized by PSMA on androgen-dependent PCa cell surfaces (LNCaP; 22Rv1), which later induce the cellular uptake of the ligand-decorated carriers via receptor-mediated endocytosis. 11 Several studies on gene targeting therapy have demonstrated the strength of ligand-modified vehicles, such as antibody, 12,13 peptide, 7,14 and APT, 6,15 in treating PSMApositive PCa cells and xenografts. The high transfection efficiency and enhanced therapeutic effect indicate that ligand-decorated nanocarriers are potentially targeted vectors to PSMA-positive PCa cells for gene delivery.…”